SLC5A2 and type 2 diabetes mellitus: The consistency of reduction in HF hospitalizations across different clinical conditions regardless of presence or absence of T2DM (as well as across the spectrum of baseline HbA1c) gives a clear indication that the mechanism of reduction in HF with SGLT2 inhibitors is independent of any glucose‐related or diabetes‐related factors.